Evercore ISI upgraded Avantor to Outperform from In Line with a price target of $26, up from $19.50. The potential of Biopharma turning around, which the firm’s survey work supports, plus the bottoming of inventory destocking and China growing make “a strong case” for Avantor, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVTR:
